Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-center, randomized open-label study to evaluate the safety and efficacy of immunotherapy with subcutaneous Maxamine (histamine dihydrochloride) plus Proleukin (interleukin-2) versus no treatment (standard of care) in patients with acute myeloid leukemia in first or subsequent complete remission (CR).

Next Previous
X
Search
Trial Profile

Multi-center, randomized open-label study to evaluate the safety and efficacy of immunotherapy with subcutaneous Maxamine (histamine dihydrochloride) plus Proleukin (interleukin-2) versus no treatment (standard of care) in patients with acute myeloid leukemia in first or subsequent complete remission (CR).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Histamine dihydrochloride (Primary) ; Aldesleukin
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Maxim Pharmaceuticals

    • Most Recent Events

    • 23 Aug 2010 Epicept Corporation received a refusal to file letter from the US FDA on the Ceplene NDA, which was based on data from this study and supporting evidence.
    • 04 Jun 2009 Six-year follow-up results have been presented at the 14th Congress of the European Hematology Association.
    • 04 Jun 2009 Six-year outcome data were presented at the European Hematology Associations 14th Congress, according to a EpiCept media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top